Synthesis of 1,4-Benzoxazepine Derivatives via a Novel Domino Aziridine Ring-Opening
dition of 5 to the in situ generated palladium(0) spe- Acknowledgements
cies leads to the palladium complex 6. This could then
We are thankful for financial support by NUST research
undergo the isocyanide-insertion process to give the
intermediate 7. Next, with the aid of the base, hydro-
ACHTUNGTRENNUNGi odic acid is extruded out of 7 to generate the eight-
funding (2011ZDJH07). We also acknowledge the Analysis
and Testing Center of Nanjing University of Science and
Technology for the NMR analyses reported in this work.
membered product 8. Finally, reductive elimination
affords 4, regenerating the palladium (0) catalyst.
In conclusion, we have demonstrated a novel and
efficient procedure for the synthesis of a new class of
substituted 1,4-benzoxazepine derivatives via a palladi-
um-catalyzed three-component domino reaction of N-
tosylaziridines, 2-iodophenols and isocyanides. This
process involved the aziridine ring-opening reaction
with 2-iodophenol, followed by palladium-catalyzed
isocyanide-insertion reaction. This domino reaction
was successful with a range of N-tosylaziridines, 2-io-
dophenols and isocyanides, and could afford the de-
sired products in moderate to high yields. More im-
portantly, this methodology may be instrumental to
the rapid construction of important 1,4-benzoxazepine
derivatives with promising biological and pharmaceut-
ical activities.
References
[
1] a) D. P. Walsh, Y.-T. Chang, Chem. Rev. 2006, 106,
2
476; b) M. D. Burke, S. L. Schreiber, Angew. Chem.
2
004, 116, 48; Angew. Chem. Int. Ed. 2004, 43, 46; c) P.
Arya, D. T. H. Chou, M.-G. Baek, Angew. Chem. 2001,
13, 351; Angew. Chem. Int. Ed. 2001, 40, 339.
1
[
2] a) T. MiKi, M. Kori, H. Mabuchi, R.-T. Tozawa, T.
Nishimoto, Y. Sugiyama, K. Teshima, H. Yukimasa, J.
Med. Chem. 2002, 45, 4571; b) R. A. Smits, H. D. Lim,
B. Stegink, R. A. Bakker, I. J. P. de Esch, R. Leurs, J.
Med. Chem. 2006, 49, 4512; c) Y. Liao, B. J. Venhuis, N.
Rodenhuis, W. Timmerman, H. Wikstrom, E. Meier,
G. D. Bartoszyk, H. Bottcher, C. A. Seyfried, S. Sun-
dell, J. Med. Chem. 1999, 42, 2235; d) L. Banfi, A. B. G.
Guanti, P. Lecinska, R. Riva, Org. Biomol. Chem. 2006,
4
, 4236; e) V. J. Merluzzi, K. D. Hargrave, M. Labadia,
K. Grozinger, M. Skoog, J. C. Wu, C. K. Shih, K.
Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R.
Faanes, R. J. Eckner, R. A. Koup, J. L. Sullivan, Science
1990, 250, 1411.
Experimental Section
General Procedure for 1,4-Benzoxazepine Derivatives
[
3] a) D. Tsvelikhovsky, S. L. Buchwald, J. Am. Chem. Soc.
A mixture of 2-iodophenol (0.55 mmol), N-tosylaziridine
2
011, 133, 14228; b) L. K. Ottesen, F. Ek, R. Olsson,
(
0.50 mmol), isocyanide (0.75 mmol), Pd
ACHTUNGTRNEN(UG PPh ) Cl (18 mg)
3 2 2
Org. Lett. 2006, 8, 1771; c) X. Xu, S. Guo, Q. Dang, J.
Chen, X. Bai, J. Comb. Chem. 2007, 9, 773; d) F. Shi,
X. Xu, L. Zheng, Q. Dang, X. Bai, J. Comb. Chem.
and Cs CO (489 mg) was stirred in toluene (4 mL) under
2
3
reflux for 24 h. Upon completion of the reaction, the mix-
ture was concentrated under vacuum and the resulting resi-
due was purified by column chromatography.
2
008, 10, 158; e) R. Fu, X. Xu, Q. Dang, X. Bai, J. Org.
Chem. 2005, 70, 10810; f) J. Yang, X. Che, Q. Dang, Z.
Wei, S. Gao, X. Bai, Org. Lett. 2005, 7, 1541; g) K.
Kamei, N. Maeda, K. Nomura, M. Shibata, R. Katsura-
gi-Ogino, M. Koyama, M. Nakajima, T. Inoue, T. Ohno,
T. Tatsuoka, Bioorg. Med. Chem. 2006, 14, 1978; h) K.
Kamei, N. Maeda, R. Ogino, M. Koyama, M. Nakaji-
ma, T. Tatsuoka, T. Ohno, T. Inoue, Bioorg. Med.
Chem. Lett. 2011, 11, 595; i) M. M. Cavalluzzi, A. Cata-
lano, C. Bruno, A. Lovece, A. Carocci, F. Corbo, C.
Franchini, G. Lentini, V. Tortorella, Tetrahedron:
Asymmetry 2007, 18, 2409.
Characterization Data of a Representative 1,4-
Benzoxazepine (4a)
1
White solid; 144–1468C; H NMR (500 MHz, CDCl ): d=
3
1
1
3
1
.14–1.15 (m, 1H), 1.32–1.47 (m, 2H), 1.59 (s, 9H), 1.50–
.60 (m, 1H), 1.77–1.84 (m, 2H), 2.06–2.08 (m, 1H), 2.31 (s,
H), 2.44–2.47 (m, 1H), 3.67–3.72 (m, 1H), 3.92–3.98 (m,
H), 6.23 (d, J=8.0 Hz, 1H), 6.91–6.98 (m, 3H), 7.07–7.12
1
3
(
m, 3H), 7.63–7.65 (m, 1H); C NMR (125 MHz, CDCl ):
3
d=20.47, 22.79, 23.51, 29.85, 32.03, 32.85, 57.72, 64.65, 79.38,
[
[
4] a) L. F. Tietze, Chem. Rev. 1996, 96, 115; b) P. J. Par-
sons, C. S. Penkett, A. J. Shell, Chem. Rev. 1996, 96,
1
1
17.35, 120.62, 124.75, 126.80, 127.65, 129.26, 132.12, 134.13,
37.72, 141.74, 156.32; MS (ESI): m/z=427 [M+H]; anal.
1
95; c) S.-I. Ikeda, Acc. Chem. Res. 2000, 33, 511;
d) M. M. Hussain, P. G. Walsh, Acc. Chem. Res. 2008,
1, 883.
5] a) G. S. Singh, M. D’hooghe, N. De Kimpe, Chem. Rev.
007, 107, 2080; b) C. A. Olsen, H. Franzyk, J. W. Jaros-
calcd. for C H N O S: C 67.58, H 7.09, N 6.57; found: C
24
30
2
3
67.67, H 7.1, N 6.55.
4
Crystallographic data for 1,4-benzoxazepine 4a have been
deposited with the Cambridge Crystallographic Data Centre
as supplementary publication no. CCDC 937174. These data
can be obtained free of charge from The Cambridge Crystal-
lographic Data Centre via www.ccdc.cam.ac.uk/data_re-
quest/cif.
2
zewski, Eur. J. Org. Chem. 2007, 1717; c) I. D. G.
Watson, L. Yu, A. K. Yudin, Acc. Chem. Res. 2006, 39,
1
94; d) X. E. Hu, Tetrahedron 2004, 60, 2701; e) J. B.
Sweeney, Chem. Soc. Rev. 2002, 31, 247; f) S. Minakata,
Acc. Chem. Res. 2009, 42, 1172.
[
6] a) J. Wu, X. Sun, Y. Li, Eur. J. Org. Chem. 2005, 4271;
b) D. Sureshkumar, S. M. Koutha, S. Chandrasekaran,
J. Am. Chem. Soc. 2005, 127, 12760; c) X.-L. Hou, R.-
H. Fan, L.-X. Dai, J. Org. Chem. 2002, 67, 5295; d) H.
Adv. Synth. Catal. 2013, 355, 3401 – 3406
ꢁ 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
3405